Answers are grounded in this paper and cite their sources.
Clinical evaluation examines sacubitril/valsartan in diabetic peritoneal dialysis patients with heart failure with preserved ejection fraction, highlighting potential therapeutic options.
To investigate the efficacy of sacubitril/valsartan in the treatment of peritoneal dialysis (PD) in patients with diabetes and heart failure with preserved ejection fraction (HFpEF).
No takes yet. Share an insight, caveat, or question.
Bian et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: